Pluripotent stem cell for treatment of cerebral infarction

Abstract

An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.

What is claimed is: 
     
         1 . A method for treating a cerebral infarction in a subject in need thereof, the method comprising: administering a cell preparation containing pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells to the subject, to treat the cerebral infarction. 
     
     
         2 . The method according to  claim 1 , wherein the cell preparation prevents and/or treats sequelae from cerebral infarction. 
     
     
         3 . The method according to  claim 1 , wherein the pluripotent stem cells positive for SSEA-3 contain a concentrated cell fraction as a result of stimulation by external stress. 
     
     
         4 . The method according to  claim 1 , wherein the pluripotent stem cells are CD105-positive. 
     
     
         5 . The method according to  claim 1 , wherein the pluripotent stem cells are CD117-negative and CD146-negative. 
     
     
         6 . The method according to  claim 1 , wherein the pluripotent stem cells are CD117-negative, CD146-negative, NG2-negative, CD34-negative, vWF-negative and CD271-negative. 
     
     
         7 . The method according to  claim 1 , wherein the pluripotent stem cells are CD34-negative, CD117-negative, CD146-negative, CD271-negative, NG2-negative, vWF-negative, Sox10-negative, Snail-negative, Slug-negative, Tyrp1-negative and Dct-negative. 
     
     
         8 . The method according to  claim 1 , wherein the pluripotent stem cells are pluripotent stem cells having all of the properties indicated below:
 (i) low or absent telomerase activity;   (ii) ability to differentiate into any of the three germ layers;   (iii) absence of demonstration of neoplastic proliferation; and,   iv) self-renewal ability.   
     
     
         9 . The method according to  claim 1 , wherein the pluripotent stem cells have the ability to differentiate into one or more cells selected from the group consisting of nerve cells, glial cells, vascular endothelial cells, and/or microglial cells. 
     
     
         10 . The method according to  claim 1 , wherein the pluripotent stem cells reduce infarct size by a mechanism involving regeneration of brain tissue.